Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Free-Cash-Flow-To-The-Firm" stands at 19.65 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 8.40 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 205.38 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 8.40 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 42.67 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 19.65 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 14.66 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -2.63 percent compared to the value the year prior.
The 1 year change in percent is -2.63.
The 3 year change in percent is 9.63.
The 5 year change in percent is 6.56.
The 10 year change in percent is 27.60.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Free Cash Flow To The Firm | 905,699,262,464.00 |
![]() | AbbVie Inc - Free Cash Flow To The Firm | 399,570,305,024.00 |
![]() | Roche Holding AG - Free Cash Flow To The Firm | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Free Cash Flow To The Firm | 280,205,508,085.11 |
![]() | Novartis AG - Free Cash Flow To The Firm | 255,096,620,580.91 |